Cardiovascular toxicities of immune therapies for cancer - a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology.
Cardiotoxicity
Cardio‐oncology
Immunotherapies
Journal
European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595
Informations de publication
Date de publication:
01 Aug 2024
01 Aug 2024
Historique:
revised:
22
05
2024
received:
12
11
2023
accepted:
03
06
2024
medline:
1
8
2024
pubmed:
1
8
2024
entrez:
1
8
2024
Statut:
aheadofprint
Résumé
The advent of immunological therapies has revolutionized the treatment of solid and haematological cancers over the last decade. Licensed therapies which activate the immune system to target cancer cells can be broadly divided into two classes. The first class are antibodies that inhibit immune checkpoint signalling, known as immune checkpoint inhibitors (ICIs). The second class are cell-based immune therapies including chimeric antigen receptor T lymphocyte (CAR-T) cell therapies, natural killer (NK) cell therapies, and tumour infiltrating lymphocyte (TIL) therapies. The clinical efficacy of all these treatments generally outweighs the risks, but there is a high rate of immune-related adverse events (irAEs), which are often unpredictable in timing with clinical sequalae ranging from mild (e.g. rash) to severe or even fatal (e.g. myocarditis, cytokine release syndrome) and reversible to permanent (e.g. endocrinopathies).The mechanisms underpinning irAE pathology vary across different irAE complications and syndromes, reflecting the broad clinical phenotypes observed and the variability of different individual immune responses, and are poorly understood overall. Immune-related cardiovascular toxicities have emerged, and our understanding has evolved from focussing initially on rare but fatal ICI-related myocarditis with cardiogenic shock to more common complications including less severe ICI-related myocarditis, pericarditis, arrhythmias, including conduction system disease and heart block, non-inflammatory heart failure, takotsubo syndrome and coronary artery disease. In this scientific statement on the cardiovascular toxicities of immune therapies for cancer, we summarize the pathophysiology, epidemiology, diagnosis, and management of ICI, CAR-T, NK, and TIL therapies. We also highlight gaps in the literature and where future research should focus.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 European Society of Cardiology.
Références
Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144:646–674. https://doi.org/10.1016/j.cell.2011.02.013
Marin‐Acevedo JA, Kimbrough EMO, Lou Y. Next generation of immune checkpoint inhibitors and beyond. J Hematol Oncol 2021;14:45. https://doi.org/10.1186/S13045‐021‐01056‐8
Larkin J, Chiarion‐Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five‐year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2019;381:1535–1546. https://doi.org/10.1056/NEJMoa1910836
Conroy M, Naidoo J. Immune‐related adverse events and the balancing act of immunotherapy. Nat Commun 2022;13:392. https://doi.org/10.1038/S41467‐022‐27960‐2
Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al.; ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow‐up. Ann Oncol 2017;28:iv119–iv142. https://doi.org/10.1093/annonc/mdx225
Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune‐checkpoint inhibitors: Epidemiology, management and surveillance. Nat Rev Clin Oncol 2019;16:563–580. https://doi.org/10.1038/S41571‐019‐0218‐0
Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta‐analysis. JAMA Oncol 2018;4:1721–1728. https://doi.org/10.1001/jamaoncol.2018.3923
Dougan M, Luoma AM, Dougan SK, Wucherpfennig KW. Understanding and treating the inflammatory adverse events of cancer immunotherapy. Cell 2021;184:1575–1588. https://doi.org/10.1016/j.cell.2021.02.011
Ibraheim H, Perucha E, Powell N. Pathology of immune‐mediated tissue lesions following treatment with immune checkpoint inhibitors. Rheumatology (Oxford) 2019;58:vii17–vii28. https://doi.org/10.1093/rheumatology/kez465
Gudd CLC, Au L, Triantafyllou E, Shum B, Liu T, Nathwani R, et al. Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor‐related hepatitis. J Hepatol 2021;75:177–189. https://doi.org/10.1016/j.jhep.2021.02.008
Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016;375:1749–1755. https://doi.org/10.1056/NEJMoa1609214
Jabkowski J, Loidl A, Auinger B, Kehrer H, Sepp N, Pichler R. Pembrolizumab‐induced thyroiditis shows PD‐L1 expressing histiocytes and infiltrating T cells in thyroid tissue – a case report. Front Immunol 2021;12:606056. https://doi.org/10.3389/fimmu.2021.606056
Su LF, Kidd BA, Han A, Kotzin JJ, Davis MM. Virus‐specific CD4+ memory‐phenotype T cells are abundant in unexposed adults. Immunity 2013;38:373–383. https://doi.org/10.1016/j.immuni.2012.10.021
Yu W, Jiang N, Ebert PJR, Kidd BA, Müller S, Lund PJ, et al. Clonal deletion prunes but does not eliminate self‐specific αβ CD8+ T lymphocytes. Immunity 2015;42:929–941. https://doi.org/10.1016/j.immuni.2015.05.001
Läubli H, Koelzer VH, Matter MS, Herzig P, Dolder Schlienger B, Wiese MN, et al. The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors. Oncoimmunology 2017;7:e1386362. https://doi.org/10.1080/2162402X.2017.1386362
Han J, Zhao Y, Shirai K, Molodtsov A, Kolling FW, Fisher JL, et al. Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy. Nat Cancer 2021;2:300–311. https://doi.org/10.1038/s43018‐021‐00180‐1
Hutchinson JA, Kronenberg K, Riquelme P, Wenzel JJ, Glehr G, Schilling HL, et al. Virus‐specific memory T cell responses unmasked by immune checkpoint blockade cause hepatitis. Nat Commun 2021;12:1439. https://doi.org/10.1038/s41467‐021‐21572‐y
Luoma AM, Suo S, Williams HL, Sharova T, Sullivan K, Manos M, et al. Molecular pathways of colon inflammation induced by cancer immunotherapy. Cell 2020;182:655–671.e22. https://doi.org/10.1016/j.cell.2020.06.001
Grigoriou M, Banos A, Hatzioannou A, Kloetgen A, Kouzis P, Aggouraki D, et al. Regulatory T‐cell transcriptomic reprogramming characterizes adverse events by checkpoint inhibitors in solid tumors. Cancer Immunol Res 2021;9:726–734. https://doi.org/10.1158/2326‐6066.CIR‐20‐0969
Osorio JC, Ni A, Chaft JE, Pollina R, Kasler MK, Stephens D, et al. Antibody‐mediated thyroid dysfunction during T‐cell checkpoint blockade in patients with non‐small‐cell lung cancer. Ann Oncol 2017;28:583–589. https://doi.org/10.1093/annonc/mdw640
Kurimoto C, Inaba H, Ariyasu H, Iwakura H, Ueda Y, Uraki S, et al. Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune‐checkpoint inhibitors. Cancer Sci 2020;111:1468–1477. https://doi.org/10.1111/cas.14363
Tahir SA, Gao J, Miura Y, Blando J, Tidwell RSS, Zhao H, et al. Autoimmune antibodies correlate with immune checkpoint therapy‐induced toxicities. Proc Natl Acad Sci U S A 2019;116:22246–22251. https://doi.org/10.1073/pnas.1908079116
Safa H, Johnson DH, Trinh VA, Rodgers TE, Lin H, Suarez‐Almazor ME, et al. Immune checkpoint inhibitor related myasthenia gravis: Single center experience and systematic review of the literature. J Immunother Cancer 2019;7:319. https://doi.org/10.1186/s40425‐019‐0774‐y
Makarious D, Horwood K, Coward JIG. Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors. Eur J Cancer 2017;82:128–136. https://doi.org/10.1016/j.ejca.2017.05.041
Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, et al. Collateral damage: Insulin‐dependent diabetes induced with checkpoint inhibitors. Diabetes 2018;67:1471–1480. https://doi.org/10.2337/dbi18‐0002
Caturegli P, di Dalmazi G, Lombardi M, Grosso F, Larman HB, Larman T, et al. Hypophysitis secondary to cytotoxic T‐lymphocyte‐associated protein 4 blockade: Insights into pathogenesis from an autopsy series. Am J Pathol 2016;186:3225–3235. https://doi.org/10.1016/j.ajpath.2016.08.020
Hammond S, Olsson‐Brown A, Gardner J, Thomson P, Ali SE, Jolly C, et al. T cell mediated hypersensitivity to previously tolerated iodinated contrast media precipitated by introduction of atezolizumab. J Immunother Cancer 2021;9:e002521. https://doi.org/10.1136/jitc‐2021‐002521
Bellinger AM, Arteaga CL, Force T, Humphreys BD, Demetri GD, Druker BJ, et al. Cardio‐oncology: How new targeted cancer therapies and precision medicine can inform cardiovascular discovery. Circulation 2015;132:2248–2258. https://doi.org/10.1161/CIRCULATIONAHA.115.010484
Boughdad S, Latifyan S, Fenwick C, Bouchaab H, Suffiotti M, Moslehi JJ, et al. 68Ga‐DOTATOC PET/CT to detect immune checkpoint inhibitor‐related myocarditis. J Immunother Cancer 2021;9:e003594. https://doi.org/10.1136/jitc‐2021‐003594
Won T, Kalinoski HM, Wood MK, Hughes DM, Jaime CM, Delgado P, et al. Cardiac myosin‐specific autoimmune T cells contribute to immune‐checkpoint‐inhibitor‐associated myocarditis. Cell Rep 2022;41:111611. https://doi.org/10.1016/j.celrep.2022.111611
Wei SC, Meijers WC, Axelrod ML, Anang NAAS, Screever EM, Wescott EC, et al. A genetic mouse model recapitulates immune checkpoint inhibitor‐associated myocarditis and supports a mechanism‐based therapeutic intervention. Cancer Discov 2021;11:614–625. https://doi.org/10.1158/2159‐8290.CD‐20‐0856
Zhang Y, Sun C, Li Y, Qin J, Amancherla K, Jing Y, et al. Hormonal therapies up‐regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis. Sci Transl Med 2022;14:eabo1981. https://doi.org/10.1126/scitranslmed.abo1981
Michel L, Helfrich I, Hendgen‐Cotta UB, Mincu RI, Korste S, Mrotzek SM, et al. Targeting early stages of cardiotoxicity from anti‐PD1 immune checkpoint inhibitor therapy. Eur Heart J 2022;43:316–329. https://doi.org/10.1093/eurheartj/ehab430
Du S, Zhou L, Alexander GS, Park K, Yang L, Wang N, et al. PD‐1 modulates radiation‐induced cardiac toxicity through cytotoxic T lymphocytes. J Thorac Oncol 2018;13:510–520. https://doi.org/10.1016/j.jtho.2017.12.002
Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA‐4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA‐4. Immunity 1995;3:541–547. https://doi.org/10.1016/1074‐7613(95)90125‐6
Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus‐like autoimmune diseases by disruption of the PD‐1 gene encoding an ITIM motif‐carrying immunoreceptor. Immunity 1999;11:141–151. https://doi.org/10.1016/S1074‐7613(00)80089‐8
Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, et al. Autoimmune dilated cardiomyopathy in PD‐1 receptor‐deficient mice. Science 2001;291:319–322. https://doi.org/10.1126/science.291.5502.319
Tarrio ML, Grabie N, Bu D, Sharpe AH, Lichtman AH. PD‐1 protects against inflammation and myocyte damage in T cell‐mediated myocarditis. J Immunol 2012;188:4876–4884. https://doi.org/10.4049/jimmunol.1200389
Moslehi J, Lichtman AH, Sharpe AH, Galluzzi L, Kitsis RN. Immune checkpoint inhibitor‐associated myocarditis: Manifestations and mechanisms. J Clin Invest 2021;131:e145186. https://doi.org/10.1172/JCI145186
Power JR, Alexandre J, Choudhary A, Ozbay B, Hayek S, Asnani A, et al.; International ICI‐Myocarditis Registry. Electrocardiographic manifestations of immune checkpoint inhibitor myocarditis. Circulation 2021;144:1521–1523. https://doi.org/10.1161/CIRCULATIONAHA.121.055816
Power JR, Alexandre J, Choudhary A, Ozbay B, Hayek SS, Asnani A, et al. Association of early electrical changes with cardiovascular outcomes in immune checkpoint inhibitor myocarditis. Arch Cardiovasc Dis 2022;115:315–330. https://doi.org/10.1016/j.acvd.2022.03.003
Moslehi JJ, Salem JE, Sosman JA, Lebrun‐Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor‐associated myocarditis. Lancet 2018;391:933. https://doi.org/10.1016/S0140‐6736(18)30533‐6
Axelrod ML, Meijers WC, Screever EM, Qin J, Carroll MG, Sun X, et al. T cells specific for α‐myosin drive immunotherapy‐related myocarditis. Nature 2022;611:818–826. https://doi.org/10.1038/s41586‐022‐05432‐3
Salem JE, Allenbach Y, Vozy A, Brechot N, Johnson DB, Moslehi JJ, et al. Abatacept for severe immune checkpoint inhibitor‐associated myocarditis. N Engl J Med 2019;380:2377–2379. https://doi.org/10.1056/NEJMc1901677
Moslehi J, Salem JE. Immune checkpoint inhibitor myocarditis treatment strategies and future directions. JACC CardioOncol 2022;4:704–707. https://doi.org/10.1016/j.jaccao.2022.11.005
Nguyen LS, Bretagne M, Arrondeau J, Zahr N, Ederhy S, Abbar B, et al. Reversal of immune‐checkpoint inhibitor fulminant myocarditis using personalized‐dose‐adjusted abatacept and ruxolitinib: Proof of concept. J Immunother Cancer 2022;10:e004699. https://doi.org/10.1136/jitc‐2022‐004699
Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al.; ORAL Surveillance Investigators. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 2022;386:316–326. https://doi.org/10.1056/NEJMoa2109927
Salem JE, Bretagne M, Abbar B, Leonard‐Louis S, Ederhy S, Redheuil A, et al. Abatacept/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune‐checkpoint inhibitor myocarditis. Cancer Discov 2023;13:1100–1115. https://doi.org/10.1158/2159‐8290.CD‐22‐1180
ClinicalTrials.gov. AbataCept for the Treatment of Immune‐cHeckpoint Inhibitors Induced mYocarditiS (ACHLYS). ClinicalTrials.gov Identifier: NCT05195645. https://classic.clinicaltrials.gov/ct2/show/NCT05195645 (30 May 2024)
ClinicalTrials.gov. Abatacept in Immune Checkpoint Inhibitor Myocarditis (ATRIUM). ClinicalTrials.gov Identifier: NCT05335928. https://www.clinicaltrials.gov/study/NCT05335928?cond=NCT05335928&rank=1 (30 May 2024)
Grabie N, Lichtman AH, Padera R. T cell checkpoint regulators in the heart. Cardiovasc Res 2019;115:869–877. https://doi.org/10.1093/cvr/cvz025
Xia W, Zou C, Chen H, Xie C, Hou M. Immune checkpoint inhibitor induces cardiac injury through polarizing macrophages via modulating microRNA‐34a/Kruppel‐like factor 4 signaling. Cell Death Dis 2020;11:575. https://doi.org/10.1038/s41419‐020‐02778‐2
Grabie N, Gotsman I, DaCosta R, Pang H, Stavrakis G, Butte MJ, et al. Endothelial programmed death‐1 ligand 1 (PD‐L1) regulates CD8+ T‐cell‐mediated injury in the heart. Circulation 2007;116:2062–2071. https://doi.org/10.1161/CIRCULATIONAHA.107.709360
Varricchi G, Galdiero MR, Tocchetti CG. Novel actors on the stage of cardiac dysfunction induced by anti‐PD1 oncological treatments. Eur Heart J 2022;43:330–332. https://doi.org/10.1093/eurheartj/ehab584
Poels K, van Leent MMT, Boutros C, Tissot H, Roy S, Meerwaldt AE, et al. Immune checkpoint inhibitor therapy aggravates T cell‐driven plaque inflammation in atherosclerosis. JACC CardioOncol 2020;2:599–610. https://doi.org/10.1016/j.jaccao.2020.08.007
Drobni ZD, Alvi RM, Taron J, Zafar A, Murphy SP, Rambarat PK, et al. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation 2020;142:2299–2311. https://doi.org/10.1161/CIRCULATIONAHA.120.049981
Drobni ZD, Gongora C, Taron J, Suero‐Abreu GA, Karady J, Gilman HK, et al. Impact of immune checkpoint inhibitors on atherosclerosis progression in patients with lung cancer. J Immunother Cancer 2023;11:e007307. https://doi.org/10.1136/jitc‐2023‐007307
Solinas C, Saba L, Sganzerla P, Petrelli F. Venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review. Thromb Res 2020;196:444–453. https://doi.org/10.1016/j.thromres.2020.09.038
Josan K, Neilan TG. Immune checkpoint inhibitors: Acute and chronic cardiovascular complications. Nat Rev Cardiol 2023;20:73–74. https://doi.org/10.1038/s41569‐022‐00827‐1
Poels K, Neppelenbroek SIM, Kersten MJ, Antoni ML, Lutgens E, Seijkens TTP. Immune checkpoint inhibitor treatment and atherosclerotic cardiovascular disease: An emerging clinical problem. J Immunother Cancer 2021;9:e002916. https://doi.org/10.1136/jitc‐2021‐002916
Chitturi KR, Xu J, Araujo‐Gutierrez R, Bhimaraj A, Guha A, Hussain I, et al. Immune checkpoint inhibitor‐related adverse cardiovascular events in patients with lung cancer. JACC CardioOncol 2019;1:182–192. https://doi.org/10.1016/j.jaccao.2019.11.013
Escudier M, Cautela J, Malissen N, Ancedy Y, Orabona M, Pinto J, et al. Clinical features, management, and outcomes of immune checkpoint inhibitor‐related cardiotoxicity. Circulation 2017;136:2085–2087. https://doi.org/10.1161/CIRCULATIONAHA.117.030571
Jain P, Gutierrez Bugarin J, Guha A, Jain C, Patil N, Shen T, et al. Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real‐world clinical data across the United States. ESMO Open 2021;6:100252. https://doi.org/10.1016/j.esmoop.2021.100252
Liu L, Zheng Q, Lee J, Ma Z, Zhu Q, Wang Z. PD‐1/PD‐L1 expression on CD4+ T cells and myeloid DCs correlates with the immune pathogenesis of atrial fibrillation. J Cell Mol Med 2015;19:1223–1233. https://doi.org/10.1111/jcmm.12467
Baik AH, Oluwole OO, Johnson DB, Shah N, Salem JE, Tsai KK, et al. Mechanisms of cardiovascular toxicities associated with immunotherapies. Circ Res 2021;128:1780–1801. https://doi.org/10.1161/CIRCRESAHA.120.315894
Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol 2022;22:85–96. https://doi.org/10.1038/S41577‐021‐00547‐6
Khadka RH, Sakemura R, Kenderian SS, Johnson AJ. Management of cytokine release syndrome: An update on emerging antigen‐specific T cell engaging immunotherapies. Immunotherapy 2019;11:851–857. https://doi.org/10.2217/imt‐2019‐0074
Alvi RM, Frigault MJ, Fradley MG, Jain MD, Mahmood SS, Awadalla M, et al. Cardiovascular events among adults treated with chimeric antigen receptor T‐cells (CAR‐T). J Am Coll Cardiol 2019;74:3099–3108. https://doi.org/10.1016/j.jacc.2019.10.038
Ganatra S, Carver JR, Hayek SS, Ky B, Leja MJ, Lenihan DJ, et al. Chimeric antigen receptor T‐cell therapy for cancer and heart: JACC Council perspectives. J Am Coll Cardiol 2019;74:3153–3163. https://doi.org/10.1016/j.jacc.2019.10.049
Pathan N, Hemingway CA, Alizadeh AA, Stephens AC, Boldrick JC, Oragui EE, et al. Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. Lancet 2004;363:203–209. https://doi.org/10.1016/S0140‐6736(03)15326‐3
Shimabukuro‐Vornhagen A, Gödel P, Subklewe M, Stemmler HJ, Schlößer HA, Schlaak M, et al. Cytokine release syndrome. J Immunother Cancer 2018;6:56. https://doi.org/10.1186/s40425‐018‐0343‐9
Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, et al. Identification of a titin‐derived HLA‐A1‐presented peptide as a cross‐reactive target for engineered MAGE A3‐directed T cells. Sci Transl Med 2013;5:197ra103. https://doi.org/10.1126/scitranslmed.3006034
Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, et al. Cardiovascular toxicity and titin cross‐reactivity of affinity‐enhanced T cells in myeloma and melanoma. Blood 2013;122:863–871. https://doi.org/10.1182/blood‐2013‐03‐490565
Andres MS, Ramalingam S, Rosen SD, Baksi J, Khattar R, Kirichenko Y, et al. The spectrum of cardiovascular complications related to immune‐checkpoint inhibitor treatment: Including myocarditis and the new entity of non inflammatory left ventricular dysfunction. Cardiooncology 2022;8:21. https://doi.org/10.1186/s40959‐022‐00147‐w
Laenens D, Yu Y, Santens B, Jacobs J, Beuselinck B, Bechter O, et al. Incidence of cardiovascular events in patients treated with immune checkpoint inhibitors. J Clin Oncol 2022;40:3430–3438. https://doi.org/10.1200/JCO.21.01808
Rubio‐Infante N, Ramírez‐Flores YA, Castillo EC, Lozano O, García‐Rivas G, Torre‐Amione G. Cardiotoxicity associated with immune checkpoint inhibitor therapy: A meta‐analysis. Eur J Heart Fail 2021;23:1739–1747. https://doi.org/10.1002/ejhf.2289
Ball S, Ghosh RK, Wongsaengsak S, Bandyopadhyay D, Ghosh GC, Aronow WS, et al. Cardiovascular toxicities of immune checkpoint inhibitors: JACC review topic of the week. J Am Coll Cardiol 2019;74:1714–1727. https://doi.org/10.1016/j.jacc.2019.07.079
Salem JE, Manouchehri A, Moey M, Lebrun‐Vignes B, Bastarache L, Pariente A, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: An observational, retrospective, pharmacovigilance study. Lancet Oncol 2018;19:1579–1589. https://doi.org/10.1016/S1470‐2045(18)30608‐9
Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, et al. Defining cardiovascular toxicities of cancer therapies: An International Cardio‐Oncology Society (IC‐OS) consensus statement. Eur Heart J 2022;43:280–299. https://doi.org/10.1093/eurheartj/ehab674
Burstein DS, Maude S, Grupp S, Griffis H, Rossano J, Lin K. Cardiac profile of chimeric antigen receptor T cell therapy in children: A single‐institution experience. Biol Blood Marrow Transplant 2018;24:1590–1595. https://doi.org/10.1016/j.bbmt.2018.05.014
Lefebvre B, Kang Y, Smith AM, Frey NV, Carver JR, Scherrer‐Crosbie M. Cardiovascular effects of CAR T cell therapy: A restrospective study. JACC CardioOncol 2020;2:193–203. https://doi.org/10.1016/j.jaccao.2020.04.012
Ganatra S, Redd R, Hayek SS, Parikh R, Azam T, Yanik GA, et al. Chimeric antigen receptor T‐cell therapy‐associated cardiomyopathy in patients with refractory or relapsed non‐Hodgkin lymphoma. Circulation 2020;142:1687–1690. https://doi.org/10.1161/CIRCULATIONAHA.120.048100
Qi K, Yan Z, Cheng H, Chen W, Wang Y, Wang X, et al. An analysis of cardiac disorders associated with chimeric antigen receptor T cell therapy in 126 patients: A single‐centre retrospective study. Front Oncol 2021;11:691064. https://doi.org/10.3389/fonc.2021.691064
Brammer JE, Braunstein Z, Katapadi A, Porter K, Biersmith M, Guha A, et al. Early toxicity and clinical outcomes after chimeric antigen receptor T‐cell (CAR‐T) therapy for lymphoma. J Immunother Cancer 2021;9:e002303. https://doi.org/10.1136/jitc‐2020‐002303
Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 2017;376:836–847. https://doi.org/10.1056/NEJMoa1609783
Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B‐cell lymphoblastic leukemia. N Engl J Med 2018;378:439–448. https://doi.org/10.1056/NEJMoa1709866
Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long‐term safety and activity of axicabtagene ciloleucel in refractory large B‐cell lymphoma (ZUMA‐1): A single‐arm, multicentre, phase 1–2 trial. Lancet Oncol 2019;20:31–42. https://doi.org/10.1016/S1470‐2045(18)30864‐7
Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al.; JULIET Investigators. Tisagenlecleucel in adult relapsed or refractory diffuse large B‐cell lymphoma. N Engl J Med 2019;380:45–56. https://doi.org/10.1056/NEJMoa1804980
Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE‐X19 CAR T‐cell therapy in relapsed or refractory mantle‐cell lymphoma. N Engl J Med 2020;382:1331–1342. https://doi.org/10.1056/NEJMoa1914347
Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 2021;384:705–716. https://doi.org/10.1056/NEJMoa2024850
Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B‐cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study. Lancet 2020;396:839–852. https://doi.org/10.1016/S0140‐6736(20)31366‐0
Lee DW, Kochenderfer JN, Stetler‐Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose‐escalation trial. Lancet 2015;385:517–528. https://doi.org/10.1016/S0140‐6736(14)61403‐3
Shalabi H, Sachdev V, Kulshreshtha A, Cohen JW, Yates B, Rosing DR, et al. Impact of cytokine release syndrome on cardiac function following CD19 CAR‐T cell therapy in children and young adults with hematological malignancies. J Immunother Cancer 2020;8:e001159. https://doi.org/10.1136/jitc‐2020‐001159
Stein‐Merlob AF, Ganatra S, Yang EH. T‐cell immunotherapy and cardiovascular disease: Chimeric antigen receptor T‐cell and bipsecific T‐cell engager therapies. Heart Fail Clin 2022;18:443–454. https://doi.org/10.1016/j.hfc.2022.02.008
Dafni U, Michielin O, Lluesma SM, Tsourti Z, Polydoropoulou V, Karlis D, et al. Efficacy of adoptive therapy with tumor‐infiltrating lymphocytes and recombinant interleukin‐2 in advanced cutaneous melanoma: A systematic review and meta‐analysis. Ann Oncol 2019;30:1902–1913. https://doi.org/10.1093/annonc/mdz398
Fradley MG, Damrongwatanasuk R, Chandrasekhar S, Alomar M, Kip KE, Sarnaik AA. Cardiovascular toxicity and mortality associated with adoptive cell therapy and tumor‐infiltrating lymphocytes for advanced stage melanoma. J Immunother 2021;44:86–89. https://doi.org/10.1097/CJI.0000000000000341
Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 2018;71:1755–1764. https://doi.org/10.1016/j.jacc.2018.02.037
D'Souza M, Nielsen D, Svane IM, Iversen K, Rasmussen PV, Madelaire C, et al. The risk of cardiac events in patients receiving immune checkpoint inhibitors: A nationwide Danish study. Eur Heart J 2021;42:1621–1631. https://doi.org/10.1093/eurheartj/ehaa884
Pirozzi F, Poto R, Aran L, Cuomo A, Galdiero MR, Spadaro G, et al. Cardiovascular toxicity of immune checkpoint inhibitors: Clinical risk factors. Curr Oncol Rep 2021;23:13. https://doi.org/10.1007/s11912‐020‐01002‐w
Lyon AR, López‐Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler‐Klein J, et al.; ESC Scientific Document Group. 2022 ESC Guidelines on cardio‐oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio‐Oncology Society (IC‐OS). Eur Heart J 2022;43:4229–4361. https://doi.org/10.1093/eurheartj/ehac244
Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, et al.; ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow‐up. Ann Oncol 2022;33:1217–1238. https://doi.org/10.1016/j.annonc.2022.10.001
Lyon AR, Dent S, Stanway S, Earl H, Brezden‐Masley C, Cohen‐Solal A, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: A position statement and new risk assessment tools from the Cardio‐Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio‐Oncology Society. Eur J Heart Fail 2020;22:1945–1960. https://doi.org/10.1002/ejhf.1920
Zlotoff DA, Hassan MZO, Zafar A, Alvi RM, Awadalla M, Mahmood SS, et al. Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. J Immunother Cancer 2021;9:e002007. https://doi.org/10.1136/jitc‐2020‐002007
Pradhan R, Nautiyal A, Singh S. Diagnosis of immune checkpoint inhibitor‐associated myocarditis: A systematic review. Int J Cardiol 2019;296:113–121. https://doi.org/10.1016/j.ijcard.2019.07.025
Lehmann LH, Heckmann MB, Bailly G, Finke D, Procureur A, Power JR, et al. Cardiomuscular biomarkers in the diagnosis and prognostication of immune checkpoint inhibitor myocarditis. Circulation 2023;148:473–486. https://doi.org/10.1161/CIRCULATIONAHA.123.062405
Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, et al. Myocarditis in the setting of cancer therapeutics: Proposed case definitions for emerging clinical syndromes in cardio‐oncology. Circulation 2019;140:80–91. https://doi.org/10.1161/CIRCULATIONAHA.118.034497
Zhang L, Awadalla M, Mahmood SS, Nohria A, Hassan MZO, Thuny F, et al. Cardiovascular magnetic resonance in immune checkpoint inhibitor‐associated myocarditis. Eur Heart J 2020;41:1733–1743. https://doi.org/10.1093/eurheartj/ehaa051
Thavendiranathan P, Zhang L, Zafar A, Drobni ZD, Mahmood SS, Cabral M, et al. Myocardial T1 and T2 mapping by magnetic resonance in patients with immune checkpoint inhibitor‐associated myocarditis. J Am Coll Cardiol 2021;77:1503–1516. https://doi.org/10.1016/j.jacc.2021.01.050
Ederhy S, Fenioux C, Cholet C, Rouvier P, Redheuil A, Cohen A, et al. Immune checkpoint inhibitor myocarditis with normal cardiac magnetic resonance imaging: Importance of cardiac biopsy and early diagnosis. Can J Cardiol 2021;37:1654–1656. https://doi.org/10.1016/j.cjca.2020.12.022
Gilon D, Iakobishvili Z, Leibowitz D. The diagnosis and management of immune checkpoint inhibitor cardiovascular toxicity: Myocarditis and beyond. Vaccines (Basel) 2022;10:304. https://doi.org/10.3390/vaccines10020304
Seferović PM, Tsutsui H, McNamara DM, Ristić AD, Basso C, Bozkurt B, et al. Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society position statement on endomyocardial biopsy. Eur J Heart Fail 2021;23:854–871. https://doi.org/10.1002/ejhf.2190
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022;24:4–131. https://doi.org/10.1002/ejhf.2333
Zhang L, Reynolds KL, Lyon AR, Palaskas N, Neilan TG. The evolving immunotherapy landscape and the epidemiology, diagnosis, and management of cardiotoxicity: JACC: CardioOncology primer. JACC CardioOncol 2021;3:35–47. https://doi.org/10.1016/j.jaccao.2020.11.012
Brahmer JR, Abu‐Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor‐related adverse events. J Immunother Cancer 2021;9:e002435. https://doi.org/10.1136/jitc‐2021‐002435
Thompson JA, Schneider BJ, Brahmer J, Achufusi A, Armand P, Berkenstock MK, et al. Management of immunotherapy‐related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2022;20:387–405. https://doi.org/10.6004/jnccn.2022.0020
Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune‐related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 2021;39:4073–4126. https://doi.org/10.1200/JCO.21.01440
Zhang L, Zlotoff DA, Awadalla M, Mahmood SS, Nohria A, Hassan MZO, et al. Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor‐associated myocarditis. Circulation 2020;141:2031–2034. https://doi.org/10.1161/CIRCULATIONAHA.119.044703
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2024;26:5–17. https://doi.org/10.1002/ejhf.3024
Waliany S, Lee D, Witteles RM, Neal JW, Nguyen P, Davis MM, et al. Immune checkpoint inhibitor cardiotoxicity: Understanding basic mechanisms and clinical characteristics and finding a cure. Annu Rev Pharmacol Toxicol 2021;61:113–134. https://doi.org/10.1146/annurev‐pharmtox‐010919‐023451
Awadalla M, Mahmood SS, Groarke JD, Hassan MZO, Nohria A, Rokicki A, et al. Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor‐related myocarditis. J Am Coll Cardiol 2020;75:467–478. https://doi.org/10.1016/j.jacc.2019.11.049
Palaskas NL, Segura A, Lelenwa L, Siddiqui BA, Subudhi SK, Lopez‐Mattei J, et al. Immune checkpoint inhibitor myocarditis: Elucidating the spectrum of disease through endomyocardial biopsy. Eur J Heart Fail 2021;23:1725–1735. https://doi.org/10.1002/ejhf.2265
Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol 2018;19:e447–e458. https://doi.org/10.1016/S1470‐2045(18)30457‐1
Dolladille C, Akroun J, Morice PM, Dompmartin A, Ezine E, Sassier M, et al. Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: A safety meta‐analysis. Eur Heart J 2021;42:4964–4977. https://doi.org/10.1093/eurheartj/ehab618
Ghadri JR, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, et al. International expert consensus document on takotsubo syndrome (part II): Diagnostic workup, outcome, and management. Eur Heart J 2018;39:2047–2062. https://doi.org/10.1093/eurheartj/ehy077
Ederhy S, Dolladille C, Thuny F, Alexandre J, Cohen A. Takotsubo syndrome in patients with cancer treated with immune checkpoint inhibitors: A new adverse cardiac complication. Eur J Heart Fail 2019;21:945–947. https://doi.org/10.1002/ejhf.1497
Lyon AR, Bossone E, Schneider B, Sechtem U, Citro R, Underwood SR, et al. Current state of knowledge on takotsubo syndrome: A position statement from the Taskforce on Takotsubo syndrome of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2016;18:8–27. https://doi.org/10.1002/ejhf.424
Schiffer WB, Deych E, Lenihan DJ, Zhang KW. Coronary and aortic calcification are associated with cardiovascular events on immune checkpoint inhibitor therapy. Int J Cardiol 2021;322:177–182. https://doi.org/10.1016/j.ijcard.2020.08.024
Vuong JT, Stein‐Merlob AF, Nayeri A, Sallam T, Neilan TG, Yang EH. Immune checkpoint therapies and atherosclerosis: Mechanisms and clinical implications: JACC state‐of‐the‐art review. J Am Coll Cardiol 2022;79:577–593. https://doi.org/10.1016/j.jacc.2021.11.048
Calabretta R, Hoeller C, Pichler V, Mitterhauser M, Karanikas G, Haug A, et al. Immune checkpoint inhibitor therapy induces inflammatory activity in large arteries. Circulation 2020;142:2396–2398. https://doi.org/10.1161/CIRCULATIONAHA.120.048708
Henderson D, Eslamian G, Poon D, Crabb S, Jones R, Sankey P, et al. Immune checkpoint inhibitor induced large vessel vasculitis. BMJ Case Rep 2020;13:e233496. https://doi.org/10.1136/bcr‐2019‐233496
Masson R, Manthripragada G, Liu R, Tavakoli J, Mok K. Possible precipitation of acute coronary syndrome with immune checkpoint blockade: A case report. Perm J 2020;24:1. https://doi.org/10.7812/TPP/20.037
Ridker PM. Anticytokine agents: Targeting interleukin signaling pathways for the treatment of stherothrombosis. Circ Res 2019;124:437–450. https://doi.org/10.1161/CIRCRESAHA.118.313129
Zhao TX, Mallat Z. Targeting the immune system in atherosclerosis: JACC state‐of‐the‐art review. J Am Coll Cardiol 2019;73:1691–1706. https://doi.org/10.1016/j.jacc.2018.12.083
Bulkley BH, Roberts WC. Steroid therapy during acute myocardial infarction. A cause of delayed healing and of ventricular aneurysm. Am J Med 1974;56:244–250. https://doi.org/10.1016/0002‐9343(74)90603‐2
Mannisi JA, Weisman HF, Bush DE, Dudeck P, Healy B. Steroid administration after myocardial infarction promotes early infarct expansion. A study in the rat. J Clin Invest 1987;79:1431–1439. https://doi.org/10.1172/JCI112971
Giugliano GR, Giugliano RP, Gibson CM, Kuntz RE. Meta‐analysis of corticosteroid treatment in acute myocardial infarction. Am J Cardiol 2003;91:1055–1059. https://doi.org/10.1016/S0002‐9149(03)00148‐6
van der Laan AM, Nahrendorf M, Piek JJ. Healing and adverse remodelling after acute myocardial infarction: Role of the cellular immune response. Heart 2012;98:1384–1390. https://doi.org/10.1136/heartjnl‐2012‐301623
Farmakis D, Filippatos G. Arrhythmias in cancer: Rhythm is gonna get you! Eur J Heart Fail 2021;23:154–156. https://doi.org/10.1002/ejhf.2079
Anker MS, von Haehling S, Coats AJS, Riess H, Eucker J, Porthun J, et al. Ventricular tachycardia, premature ventricular contractions, and mortality in unselected patients with lung, colon, or pancreatic cancer: A prospective study. Eur J Heart Fail 2021;23:145–153. https://doi.org/10.1002/ejhf.2059
Mir H, Alhussein M, Alrashidi S, Alzayer H, Alshatti A, Valettas N, et al. Cardiac complications associated with checkpoint inhibition: A systematic review of the literature in an important emerging area. Can J Cardiol 2018;34:1059–1068. https://doi.org/10.1016/j.cjca.2018.03.012
Farmakis D. Anticoagulation for atrial fibrillation in active cancer: What the cardiologists think. Eur J Prev Cardiol 2021;28:608–610. https://doi.org/10.1093/eurjpc/zwaa087
Herrmann J. Adverse cardiac effects of cancer therapies: Cardiotoxicity and arrhythmia. Nat Rev Cardiol 2020;17:474–502. https://doi.org/10.1038/s41569‐020‐0348‐1
Ghosh AK, Chen DH, Guha A, Mackenzie S, Walker JM, Roddie C. CAR T cell therapy‐related cardiovascular outcomes and management: Systemic disease or direct cardiotoxicity? JACC CardioOncol 2020;2:97–109. https://doi.org/10.1016/j.jaccao.2020.02.011
Salem JE, Ederhy S, Lebrun‐Vignes B, Moslehi JJ. Cardiac events associated with chimeric antigen receptor T‐cells (CAR‐T): A VigiBase perspective. J Am Coll Cardiol 2020;75:2521–2523. https://doi.org/10.1016/j.jacc.2020.02.070
Guha A, Addison D, Jain P, Gutierrez JM, Ghosh A, Roddie C, et al. Cardiovascular events associated with chimeric antigen receptor T cell therapy: Cross‐sectional FDA Adverse Events Reporting System analysis. Biol Blood Marrow Transplant 2020;26:2211–2216. https://doi.org/10.1016/j.bbmt.2020.08.036
Pudil R, Mueller C, Čelutkienė J, Henriksen PA, Lenihan D, Dent S, et al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: A position statement from the Cardio‐Oncology Study Group of the Heart Failure Association and the Cardio‐Oncology Council of the European Society of Cardiology. Eur J Heart Fail 2020;22:1966–1983. https://doi.org/10.1002/ejhf.2017
Goldman A, Maor E, Bomze D, Liu JE, Herrmann J, Fein J, et al. Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T‐cell therapy. J Am Coll Cardiol 2021;78:1800–1813. https://doi.org/10.1016/j.jacc.2021.08.044
Maus MV, Alexander S, Bishop MR, Brudno JN, Callahan C, Davila ML, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell‐related adverse events. J Immunother Cancer 2020;8:e001511. https://doi.org/10.1136/jitc‐2020‐001511
Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 2019;25:625–638. https://doi.org/10.1016/j.bbmt.2018.12.758
Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, et al. Management of immune‐related adverse events in patients treated with chimeric antigen receptor T‐cell therapy: ASCO guideline. J Clin Oncol 2021;39:3978–3992. https://doi.org/10.1200/JCO.21.01992
Caimi PF, Pacheco Sanchez G, Sharma A, Otegbeye F, Ahmed N, Rojas P, et al. Prophylactic tocilizumab prior to anti‐CD19 CAR‐T cell therapy for non‐Hodgkin lymphoma. Front Immunol 2021;12:745320. https://doi.org/10.3389/fimmu.2021.745320
Kadauke S, Myers RM, Li Y, Aplenc R, Baniewicz D, Barrett DM, et al. Risk‐adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B‐cell acute lymphoblastic leukemia: A prospective clinical trial. J Clin Oncol 2021;39:920–930. https://doi.org/10.1200/JCO.20.02477
Barac A, Sharon E. From detecting signals to understanding cardiovascular toxicities of cancer therapies: All the light we could see. J Am Coll Cardiol 2021;78:1814–1816. https://doi.org/10.1016/j.jacc.2021.09.008
World Health Organization. WHOQOL: Measuring Quality of Life. https://www.who.int/tools/whoqol (20 May 2024)
Koop Y, van Zadelhof N, Maas AHEM, Atsma F, el Messaoudi S, Vermeulen H. Quality of life in breast cancer patients with cancer treatment‐related cardiac dysfunction: A qualitative study. Eur J Cardiovasc Nurs 2022;21:235–242. https://doi.org/10.1093/eurjcn/zvab057
Berg SK, Rasmussen TB, Thrysoee L, Lauberg A, Borregaard B, Christensen AV, et al. DenHeart: Differences in physical and mental health across cardiac diagnoses at hospital discharge. J Psychosom Res 2017;94:1–9. https://doi.org/10.1016/j.jpsychores.2017.01.003
Harrison JM, Davis MA, Barton DL, Janz NK, Pressler SJ, Friese CR. Functional status and quality of life among breast cancer survivors with heart failure: Results of the Medicare Health Outcomes Survey. Support Care Cancer 2017;25:2463–2473. https://doi.org/10.1007/s00520‐017‐3653‐4
Ryerson AB, Wasilewski‐Masker K, Border WL, Goodman M, Meacham L, Austin H, et al. Pediatric quality of life in long‐term survivors of childhood cancer treated with anthracyclines. Pediatr Blood Cancer 2016;63:2205–2211. https://doi.org/10.1002/pbc.26149